Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting were told.
Oncology Nurse Advisor